KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) EBT Margin (2017 - 2025)

Bionano Genomics' EBT Margin history spans 7 years, with the latest figure at 115.22% for Q3 2025.

  • For Q3 2025, EBT Margin rose 61296.0% year-over-year to 115.22%; the TTM value through Sep 2025 reached 134.24%, up 27311.0%, while the annual FY2024 figure was 363.87%, 27970.0% up from the prior year.
  • EBT Margin for Q3 2025 was 115.22% at Bionano Genomics, down from 101.69% in the prior quarter.
  • Across five years, EBT Margin topped out at 47.93% in Q1 2025 and bottomed at 1207.63% in Q3 2023.
  • The 5-year median for EBT Margin is 445.07% (2021), against an average of 419.51%.
  • The largest annual shift saw EBT Margin plummeted -76751bps in 2023 before it soared 61296bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 455.66% in 2021, then rose by 1bps to 448.84% in 2022, then increased by 9bps to 409.73% in 2023, then surged by 40bps to 246.53% in 2024, then surged by 53bps to 115.22% in 2025.
  • Per Business Quant, the three most recent readings for BNGO's EBT Margin are 115.22% (Q3 2025), 101.69% (Q2 2025), and 47.93% (Q1 2025).